anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: Aim: To establish the peculiarities of the hormonal background in women with abnormal uterine bleeding and extragenital disorders.
PATIENTS AND METHODS: Materials and Methods: The study involved examination of 100 women of reproductive age with concomitant ED and AUB (MG). CG included 50 healthy women. MG women were additionally divided into subgroups depending on the detected pathological changes in the uterine cavity. When examining the hormonal status, concentrations of FSH, LH, estradiol, progesterone, and leptin in BS were determined. Additionally, the level of 25-hydroxyvitamin D ((25-OH) D) was determined.
RESULTS: Results: The decrease in FSH level in subgroups of GP, PSL, EH, EHL was 1.8-2.4 times (KWT, p<0.01). LH in BS of MG patients was statistically lower than that of CG patients (MWT, p=0.0083). The lowest level of LH was registered in patients with EHL, which was 2 times lower than this indicator in CG. A statistically significant increase in the level of estradiol was registered in 73% of MG patients (MWT, p=0.044). The lowest level of progesterone was registered in patients with EHL - 8.40, which is 4.7 times lower than in CG (MWT, p=0.0021). A statistically significant increase in the level of leptin in BS was observed in MG patients (KWT, p=0.0021). The highest level of leptin was found in women with AFP, 2.3 times higher than CG indicators. A statistically significant correlation between the level of leptin and BMI (r=0.86, p=0.011) and a statistically significant (p=0.023) correlation between the level of leptin and estradiol in BS of patients of the examined groups (r=0.42) were revealed. In 87% of MG women, vitamin D deficiency was observed in BS (KWT, p=0.03). A statistically significant (p=0.01) negative correlation between the level of estradiol and vitamin D in the BS of female patients was revealed (r=-0.61, p=0.01).
CONCLUSION: Conclusions: Women of reproductive age with AUB and ED were found to have disorders in the hypothalamic-pituitary-ovarian system. Most patients are characterized by an elevated level of leptin, the concentration of which is closely correlated with BMI, and an elevated level of estradiol is correlated with the level of vitamin D.
BACKGROUND AND AIMS: Sexually transmitted infections (STIs) are a significant global public health challenge due to their high incidence rate and potential for severe consequences when early intervention is neglected. Research shows an upward trend in absolute cases and DALY numbers of STIs, with syphilis, chlamydia, trichomoniasis, and genital herpes exhibiting an increasing trend in age-standardized rate (ASR) from 2010 to 2019. Machine learning (ML) presents significant advantages in disease prediction, with several studies exploring its potential for STI prediction. The objective of this study is to build males-based and females-based STI risk prediction models based on the CatBoost algorithm using data from the National Health and Nutrition Examination Survey (NHANES) for training and validation, with sub-group analysis performed on each STI. The female sub-group also includes human papilloma virus (HPV) infection.
METHODS: The study utilized data from the National Health and Nutrition Examination Survey (NHANES) program to build males-based and females-based STI risk prediction models using the CatBoost algorithm. Data was collected from 12,053 participants aged 18 to 59 years old, with general demographic characteristics and sexual behavior questionnaire responses included as features. The Adaptive Synthetic Sampling Approach (ADASYN) algorithm was used to address data imbalance, and 15 machine learning algorithms were evaluated before ultimately selecting the CatBoost algorithm. The SHAP method was employed to enhance interpretability by identifying feature importance in the model's STIs risk prediction.
RESULTS: The CatBoost classifier achieved AUC values of 0.9995, 0.9948, 0.9923, and 0.9996 and 0.9769 for predicting chlamydia, genital herpes, genital warts, gonorrhea, and overall STIs infections among males. The CatBoost classifier achieved AUC values of 0.9971, 0.972, 0.9765, 1, 0.9485 and 0.8819 for predicting chlamydia, genital herpes, genital warts, gonorrhea, HPV and overall STIs infections among females. The characteristics of having sex with new partner/year, times having sex without condom/year, and the number of female vaginal sex partners/lifetime have been identified as the top three significant predictors for the overall risk of male STIs. Similarly, ever having anal sex with a man, age and the number of male vaginal sex partners/lifetime have been identified as the top three significant predictors for the overall risk of female STIs.
CONCLUSIONS: This study demonstrated the effectiveness of the CatBoost classifier in predicting STI risks among both male and female populations. The SHAP algorithm revealed key predictors for each infection, highlighting consistent demographic characteristics and sexual behaviors across different STIs. These insights can guide targeted prevention strategies and interventions to alleviate the impact of STIs on public health.
PROBLEM TO BE SOLVED: To obtain the subject medicine effective for allergic diseases, etc., capable of suppressing the immune response of type 2 helper cell side, by including a compound for enhancing the immune response of type 2 helper cell side as an active ingredient. SOLUTION: This medicine contains a compound of formula I (R1 is a 1-10C alkyl, a 1-6C hydroxyalkyl, etc.; R2 is H or a 1-8C alkyl; R3 is a 1-4C alkoxy, a halogen, etc.; (n) is an integer of 0-2 and when (n) is 2, R3 has carbon atoms not exceeding six in total) or its acid addition salt. The compound of formula I is readily obtained by applying a known method. For example, a compound of formula II may be cited as the compound of formula I. Consequently a therapeutic agent or a preventive effective for diseases caused by abnormal advance of type 2 helper cell side, for example, allergic diseases and autoimmune diseases such as systemic lupus erythematosus can be provided.
Participants will receive JNJ-40411813 twice a day (bid) up to 12 weeks in double blind period. Up to 3 different doses (low, medium, high) of JNJ-40411813 will be administered in this study. Participants will also receive concomitant anti-epileptic drugs (AEDs) one of which must include levetiracetam or brivaracetam. Immediately after the last study drug intake by the participants in the double-blind period, participants will enter into a 2-year open label extension (OLE) period and continue receiving JNJ-40411813 as well as the AEDs during OLE period.
Compounds which bind to toxins associated with enteric bacterial infection, compositions including the compounds, methods for the neutralization of toxins in a patient, and methods for the diagnosis of bacterial and viral infections are disclosed. Toxins which can be bound by the compounds include pentameric toxins, for example SLTs, such as those from salmonella, camylobacter and other bacteria, verotoxins from E. coli, cholera toxin, clostridium difficile toxins A and B, bacterial pili from enteropathogenic E. coli (EPEC) and enterotoxigenic E. coli (ETEC) and viral lectins such as viral hemagglutinins.  The compounds include a core molecule bound to a plurality of linker arms, which in turn are bound to a plurality of bridging moieties, which in turn are bound to at least one, and preferably, two or more ligands which bind to the toxin. Examples of suitable ligands include di- and for trisaccharide moieties. The di- or tri-saccharide moieties themselves are active in binding to the SLTs. The presence of a plurality of briged dimers of the ligands is responsible for the increased binding affinity of the compounds relative to the ligands themselves. In one embodiment, the compounds, when administered in a timely fashion to a patient suffering from enteric E. coli infection, inhibit progression of this infection into hemolytic uremic syndrome (HUS).
CARISA (Combination Assessment of Ranolazine In Stable Angina) was a study in 823 chronic angina patients randomized to receive 12 weeks of treatment with twice-daily ranolazine extended-release tablets 750 mg, 1000 mg, or placebo, who also continued on daily doses of atenolol 50 mg, amlodipine 5 mg, or diltiazem CD 180 mg. Sublingual nitrates were used in this study as needed.

In this trial, statistically significant (p <0.05) increases in modified Bruce treadmill exercise duration and time to angina were observed for each ranolazine extended-release tablets dose versus placebo, at both trough (12 hours after dosing) and peak (4 hours after dosing) plasma levels, with minimal effects on blood pressure and heart rate. The changes versus placebo in exercise parameters are presented in Table 1. Exercise treadmill results showed no increase in effect on exercise at the 1000 mg dose compared to the 750 mg dose.

The effects of ranolazine extended-release tablets on angina frequency and nitroglycerin use are shown in Table 2. 

Tolerance to ranolazine extended-release tablets did not develop after 12 weeks of therapy. Rebound increases in angina, as measured by exercise duration, have not been observed following abrupt discontinuation of ranolazine extended-release tablets.

Ranolazine extended-release tablets has been evaluated in patients with chronic angina who remained symptomatic despite treatment with the maximum dose of an antianginal agent. In the ERICA (Efficacy of Ranolazine In Chronic Angina) trial, 565 patients were randomized to receive an initial dose of ranolazine extended-release tablets 500 mg twice daily or placebo for 1 week, followed by 6 weeks of treatment with ranolazine extended-release tablets 1000 mg twice daily or placebo, in addition to concomitant treatment with amlodipine 10 mg once daily. In addition, 45% of the study population also received long-acting nitrates. Sublingual nitrates were used as needed to treat angina episodes. Results are shown in Table 3. Statistically significant decreases in angina attack frequency (p=0.028) and nitroglycerin use (p=0.014) were observed with ranolazine extended-release tablets compared to placebo. These treatment effects appeared consistent across age and use of long-acting nitrates.

Gender

Effects on angina frequency and exercise tolerance were considerably smaller in women than in men. In CARISA, the improvement in Exercise Tolerance Test (ETT) in females was about 33% of that in males at the 1000 mg twice-daily dose level. In ERICA, where the primary endpoint was angina attack frequency, the mean reduction in weekly angina attacks was 0.3 for females and 1.3 for males.

Race

There were insufficient numbers of non-Caucasian patients to allow for analyses of efficacy or safety by racial subgroup.
This study will be conducted at El hadra university hospital, Alexandria, Egypt. Study Design: Randomized Parallel Groups Clinical Trial. Participants: Sixty patients of both genders with unilateral shoulder impingement syndrome, with age range from 30-40 years will be randomly assigned to 1 of 3 groups. All patients will be referred by the orthopedic surgeon who will diagnose shoulder impingement syndrome based on clinical and radiological examination. Group 1: twenty patients will receive concentric training of rotator cuff muscles while applying blood flow restriction for 4 weeks. Group 2: twenty patients will receive eccentric training of rotator cuff muscles while applying blood flow restriction for 4 weeks. Group 3: twenty patients will receive isometric training of rotator cuff muscles while applying blood flow restriction for 4 weeks. The assessment for all groups will be done at baseline and after 4 weeks.
Standard of Care plus an ARB to be taken orally twice daily for up to 10 days or until discharged from the hospital, whichever occurs first. Investigator may increase dose on days 2 - 10 if confident the subject will tolerate.
The present teaching relates to medical suggestion searching. In one example, data related to a medication drug are obtained. One or more candidate prescription strings are identified from the obtained data. Each of the candidate prescription strings is associated with a plurality of attributes. Each of the one or more candidate prescription strings is automatically processed based on at least one model to generate one or more prescription strings each with an associated ranking. At least some of the generated one or more prescription strings and the associated rankings are stored for future use.
FIELD: medicine, biochemistry. SUBSTANCE: method involves addition of urotropin or alkaline metal salts solution to acetate solution of collagen treated with alkali at stirring to pH 4.3-5.3 in mixture. Precipitated fibrils are washed out with water and liquid phase excess is removed to protein content 1.20-3.50%. Then paste-like substance is stabilized with glutaric aldehyde, treated with hydrogen peroxide solution, washed out, liquid phase excess is removed and sterilized by irradiation at dose 15-25 kGr. Collagen fibrils can be isolated in the presence of acid glycoseaminoglycans (up to 10% of collagen content). Base can contain drugs that are resistant to irradiation, hydroxylapatite or osseous flour powder. Method can be used for preparing sterile base used for wound treatment and implantation. EFFECT: improved method of fibrillated collagen preparing. 5 cl, 6 ex
Healthcare professionals should pay special attention to accurate calculation of the dose of zidovudine, transcription of the medication order, dispensing information, and dosing instructions to minimize risk for medication dosing errors.

Prescribers should calculate the appropriate dose of zidovudine for each child based on body weight (kg) and should not exceed the recommended adult dose.

Before prescribing zidovudine capsules, children should be assessed for the ability to swallow capsules. If a child is unable to reliably swallow a zidovudine capsule, the zidovudine syrup formulation should be prescribed.

The recommended oral dosage in pediatric patients aged 4 weeks to less than 18 years and weighing greater than or equal to 4 kg is provided in Table 1. Zidovudine syrup should be used to provide accurate dosage when capsules are not appropriate.

Alternatively, dosing for zidovudine can be based on body surface area (BSA) for each child. The recommended oral dose of zidovudine is 480 mg per m2 per day in divided doses (240 mg per m2 twice daily or 160 mg per m2 three times daily). In some cases the dose calculated by mg per kg will not be the same as that calculated by BSA.
Atrial fibrillation (AF) is a major public health burden worldwide. Heart failure (HF) is one of the most common causes of death in patients with AF. Clinical trials have indicated that SGLT2i can reduce the risk of AF and HF in patients with diabetes, and improve the prognosis in patients with HF. However, whether SGLT2i can improve cardiac function and reduce the risk of HF in patients with AF remains unclear. The purpose of the HENA-AF trial is to evaluate the effects of henagliflozin on cardiac structure, function, and biomarkers of HF in patients with AF.

The HENA-AF trial will include approximately 100 persistent AF patients with enlarged left atrium and at least another cardiovascular risk factor. Participants will be randomized to henagliflozin or placebo. Cardiac MRI will be performed at baseline and at 6 months to measure the changes in cardiac structure and function. The primary hypothesis is that henagliflozin will reduce the left atrial volume index at 6 months in patients with AF.
All eligible patients with Chronic Obstructive Pulmonary Disease (COPD) and Alpha one anti-trypsin (A1AT) deficiency were included in this group. The observational period is 156 weeks.
Patients receive azacitidine SC or IV over 1 hour daily on days 1-5, and venetoclax PO daily on days 1-14. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
Intervention Group : The women in this group will receive a 4-week Mindfulness-Based Stress Reduction program in addition to routine outpatient clinic follow-up at the relevant institution. Before the implementation of the Mindfulness-Based Stress Reduction program, the women in the intervention group will be administered the Informed Voluntary Consent Form, Descriptive Characteristics Information Form, Perceived Stress Scale, DASS-21 and salivary cortisol measurements for pre-test measurements. After the mindfulness program, follow-up tests will be conducted in the 4th week. In the 8th week, the post-test will be conducted. In the post-test and follow-up test; Perceived Stress Scale, DASS-21 and salivary cortisol measurements will be applied.
IMMUNEPOTENT-CRP (I-CRP) was supplied in a 5 Unit (U) per vial presentation. One U is defined as the lyophilized product obtained from the dialysis of 1×10\^8 bovine spleen cells. The dosing schedule extended over 14 days. On the first day (Day 0), outpatients ingested seven doses at two-hour intervals each one. From days one through four, four doses were taken one every four hours, and from days five to thirteen, three doses were consumed one every eight hours.
Colonoscopy is a primary screening and follow-up tool to detect colorectal cancer, a third leading cause of cancer death in Taiwan. Most colorectal cancers (CRCs) arise from preexisting adenomas, and the adenoma-carcinoma sequence offers an opportunity for the screening and prevention of CRCs. The removal of adenomatous polyps can lower the incidence of CRCs and result in reduced motality from CRCs. The adenoma detection rate, the proportion of screening colonoscopies performed by a endoscopist that detect at least one colorectal adenoma or adenocarcinoma, has been recommended as a quality indicator. The adenoma detection rate was inversely associated with the risks of interval colorectal cancer, advanced-stage interval cancer, and fatal interval cancer. However, adenoma detection rates vary widely among endoscopists in both academic and community settings. Polyp miss rates as high as 20% have been reported for high definition resolution colonoscopy. An improvement in adenoma detection rate at screening colonoscopy, translates into reduced risks of interval colorectal cancer and colorectal cancer death. Computer-aided detection of polyps might assist endoscopists to reduce the miss rate and enhance screening performance during colonoscopy. Computer-aided diagnosis and computer-aided detection are computerized systems that learn and inference in medical fields. Computer-aided diagnosis has been developed in colon polyp classification.

Computer-assisted image analysis has the potential to further aid adenoma detection but has remained underdeveloped. A notable benefit of such a system is that no alteration of the colonoscope or procedure is necessary. Machine learning with a deep neural network has been successfully applied to many areas of science and technology, such as object recognition and detection of computer vision, speech recognition, natural language processing. We developed an artificial intelligent computer system (PX-1) with a deep neural network to analyze real-time video signals from the endoscopy station. This randomised controlled trial compared ADR between computer-assisted colonoscopy and standard colonoscopy.
This arm is the control group. They will receive usual oncology care from their regular oncologist and care team with no change in their care plan or treatment as a result of the intervention. Outcomes will be assessed at each of the following times: baseline, 3-months, 6-months, and 12-months.
The oral mucosa is made up of an epithelium supported by the lamina propria and the submucosa. When the mucosa is damaged, wound healing is characterized by distinct, sequential phases. How does the healing process proceed? Both primary and secondary wound healing, encompasses haemostasis, inflammation, proliferation, and remodelling. Secondary healing also involves a granulation phase to cover the wound. Saliva and the oral microbiome play a role in the healing process, too. Smoking, certain systemic disorders and medication can have a negative effect on the healing process.
Obesity is associated with low-grade inflammation in adipose tissue (AT) and dysfunctional adipocytes producing inflammatory molecules. A recent study reveals profound MAIT cell abnormalities inpatients harboring metabolic disorders, suggesting their potential role in these pathologies. Now the inventors show that MAIT cells induce adipose tissue and ileum dysfunction and inflammation in obese mice. Moreover, the inventors show that a treatment with an agent capable of inhibiting the activation of MAIT cells (i.e. Ac-6-FP) during high fat diet (HFD) improved metabolic parameters and in particular insulin sensitivity. Thus the present invention relates to the use of an agent capable of inhibiting the activation of MAIT cells for the treatment of obesity and obesity-related disorders.
Participants will be prescribed a sleep schedule that allows them to obtain at least 1h more time in bed compared to their typical school week schedule. In addition, participants will be provided with pharmaceutical-grade exogenous melatonin and instructed to take 500mcg 2 hours before their scheduled bedtime. They will also be asked reduce evening light exposure starting 2 hours before bedtime by limiting household lights and dimming electronics. In the mornings, participants will be exposed to bright light for 30 minutes after waking by wearing provided ReTimer light therapy glasses.
An impregnated support (a) comprises absorbent material, 0.01-2mm thick and 1-1000 square cm in size, impregnated with a compsn. for hair treatment, (b) contains no oxidising agent and no mercaptans or thio cpds., and (c) is sealed into sachets, e.g. sealed and/or plastic bags. The support is of absorbent paper and/or a fleece and/or a textile, of natural and/or synthetic material, and esp. has thickness 0.02-1.2mm, flat wt. 10-40 g/square m, wet tensile strength at least 5N, and dry tensile strength at least 15 N. The impregnant is a pourable compsn. of low and/or high viscosity, and may be free from water. The wt. of the impregnant is 1-10 x the wt. of the support. USE/ADVANTAGE - The material is used in caring for the hair or improving the structure of the hair. The sachets can be carried in the pocket. In use, contact with the scalp, face or eyes is avoided.
The invention discloses a care medicine composition used before operative anesthesia and a preparation method thereof. The medicine composition is composed of Chinese herbal medicinal ingredients and Western medicinal ingredients. The Chinese herbal medicinal ingredients mainly comprise fruits of Celastrus rosthornianus Loes, sow thistle flower and seeds, rhapis excelsa, the root of Laxleaf Beautifulflower Millettia, all-grass of auriculate dichrocephala, pine among the Indian Bread, fructus terminaliae billericae, aizoon stonecrop herb, valerian, sandalwood extract and crowndaisy chrysanthemum extract. The Western medicinal ingredients mainly comprise aminomethylbenzoic acid, diaminocaproic acid, taurine and cefuroxime. The care medicine composition is scientifically matched according to different medicine effects and characteristics of Chinese and western medicine, is applied to according to indications, has the effects of soothing nerves and calming heart, relieving pain and removing swelling, resisting bacteria and diminishing inflammation, stopping bleeding, enhancing human body immunocompetence and resisting virus infection, and effectively eases preoperative tension, anxiety, fear and other psychic reactions of a patient. The care medicine composition used before operative anesthesia is simple in preparation technology, remarkable in treatment effect and gentle in medicine effect and has the good medical value.